Episode Description
Obesity drug development is moving faster than any other metabolic area and success now depends on more than efficacy alone. Sponsors must balance evolving science, sustained safety, and operational scale to generate decision-ready data in a highly competitive landscape.
In this Novotech podcast (audio adaptation of a recent Novotech webinar), industry experts discuss what is changing in obesity R&D and how sponsors can design trials that start quickly, recruit at scale, and remain viable over the long term.